S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?

LAVA Therapeutics (LVTX) Earnings Date, Estimates & Call Transcripts

$2.83
-0.11 (-3.74%)
(As of 04/18/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Jun. 13Estimated
Actual EPS
(Mar. 20)
-$0.24 Missed By -$0.40
Consensus EPS
(Mar. 20)
$0.16
Skip Charts & View Estimated and Actual Earnings Data

LVTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LVTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

LAVA Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($1.35)($0.39)($0.72)
Q2 20243($1.59)($0.39)($0.80)
Q3 20243($1.57)($0.40)($0.80)
Q4 20243($0.83)($0.40)($0.55)
FY 202412($5.34)($1.58)($2.86)

LVTX Earnings Date and Information

LAVA Therapeutics last announced its earnings data on March 20th, 2024. The reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.16 by $0.40. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $25 million. LAVA Therapeutics has generated ($1.59) earnings per share over the last year (($1.59) diluted earnings per share). Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.77) per share. LAVA Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 13th, 2024 based off prior year's report dates.

LAVA Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
6/13/2024
Estimated)
------- 
3/20/2024Q4 2023$0.16($0.24)($0.40)($0.24)$25.00 million$0.35 million
11/16/2023Q3 2023($0.49)($0.34)+$0.15($0.34)-$0.05 million
8/22/2023Q2 2023($0.50)($0.48)+$0.02($0.48)$2.50 million$5.14 million
6/8/2023Q1 2023($0.49)($0.53)($0.04)($0.53)-$1.22 million
4/11/2023Q4 2022-($0.57)($0.57)($0.57)-$2.64 million
11/16/2022Q3 2022($0.07)$0.04+$0.11$0.04$25.00 million$15.26 million
9/13/2022Q2 2022($0.61)($0.31)+$0.30($0.31)$1.00 million$0.47 million
5/17/2022Q1 2022($0.95)($0.41)+$0.54($0.41)-$1.00 million
3/24/2022Q4 2021($0.38)($0.38)-($0.38)$1.32 million$1.00 million
11/14/2021Q3 2021($0.28)($0.27)+$0.01($0.27)-$2.10 million
8/15/2021Q2 2021($0.24)($0.28)($0.04)($0.28)-$1.08 million
5/20/2021Q1 2021($0.27)($12.28)($12.01)($12.28)-$1.11 million

LAVA Therapeutics Earnings - Frequently Asked Questions

When is LAVA Therapeutics's earnings date?

LAVA Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 13th, 2024 based off last year's report dates. Learn more on LVTX's earnings history.

Did LAVA Therapeutics beat their earnings estimates last quarter?

In the previous quarter, LAVA Therapeutics (NASDAQ:LVTX) missed the analysts' consensus estimate of $0.16 by $0.40 with a reported earnings per share (EPS) of ($0.24). Learn more on analysts' earnings estimate vs. LVTX's actual earnings.

How much revenue does LAVA Therapeutics generate each year?

LAVA Therapeutics (NASDAQ:LVTX) has a recorded annual revenue of $6.77 million.

How much profit does LAVA Therapeutics generate each year?

LAVA Therapeutics (NASDAQ:LVTX) has a recorded net income of -$41.97 million. LVTX has generated -$1.59 earnings per share over the last four quarters.

What is LAVA Therapeutics's EPS forecast for next year?

LAVA Therapeutics's earnings are expected to decrease from ($1.41) per share to ($1.77) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:LVTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners